Feature of amenorrhea in postoperative tamoxifen users with breast cancer.
- Author:
Hoon KIM
1
;
Wonshik HAN
;
Seung Yup KU
;
Chang Suk SUH
;
Seok Hyun KIM
;
Young Min CHOI
Author Information
- Publication Type:Original Article
- Keywords: Tamoxifen; Amenorrhea; Breast Neoplasms
- MeSH: Amenorrhea*; Breast Neoplasms*; Breast*; Estradiol; Female; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Humans; Hyperthyroidism; Medical Records; Menstruation; Prevalence; Recurrence; Retrospective Studies; Tamoxifen*; Thyrotropin
- From:Journal of Gynecologic Oncology 2017;28(2):e10-
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: Tamoxifen has been used to prevent the recurrence of breast cancer. However, tamoxifen-users frequently experience amenorrhea and it can be confused from that caused by other hormonal abnormalities. In amenorrheic patients without breast cancer, clinicians usually measure the sex hormone levels that are known to be associated with ovarian or menstrual function. This study aimed to investigate the feature of female sex hormones in premenopausal breast cancer patients undergoing tamoxifen treatment. METHODS: The medical records of fifty-nine premenopausal breast cancer patients who underwent tamoxifen treatment were reviewed retrospectively. The study population consisted of amenorrheic patients (n=36) and patients with menstruation (n=23). Serum hormone levels were measured either specifically between cycle days 2 and 5 in menstruating patients or at any time in amenorrheic participants. RESULTS: Serum levels of lutenizing hormone and estradiol were not statistically different according to the presence of menstruation. Serum follicle stimulating hormone level was significantly higher in amenorrheic patients (8.1±5.7 mIU/mL) than those in menstruating subjects (5.1±2.2 mIU/mL) (p=0.01). Serum concentration of thyroid stimulating hormone was lower in patients with amenorrhea (1.5±0.9 vs. 2.3±2.2 μIU/mL, p=0.04), although the prevalence of hypo- or hyperthyroidism was not different according to the pattern of menstruation. CONCLUSION: Menstruation status and hormone levels can be influenced by tamoxifen use in reproductive age breast cancer patients. Physicians should be attentive to the alteration of pituitary hormone levels in addition to sex steroid hormones in this population.
